[Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients].

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Enfermedades Infecciosas y Microbiologia Clinica

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 16159543
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of Cytomegalovirus Infection after Solid-Organ or Stem-Cell Transplantation

  2012cited by this paper
• Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value.

  2005cited by this paper
• A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.

  2004cited by this paper
• LEFLUNOMIDE THERAPY FOR CYTOMEGALOVIRUS DISEASE IN RENAL ALLOGRAFT RECEPIENTS

  2004cited by this paper
• Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation

  2004cited by this paper
• Management of CMV infections: recommendations from the infectious diseases working party of the EBMT

  2004cited by this paper
• CYTOMEGALOVIRUS INFECTION IN ORGAN-TRANSPLANT RECIPIENTS: DIAGNOSTIC VALUE OF PP65 ANTIGEN TEST, QUALITATIVE POLYMERASE CHAIN REACTION (PCR) AND QUANTITATIVE TAQMAN PCR

  2004cited by this paper
• Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients1

  2004cited by this paper
• Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.

  2004cited by this paper
• Maribavir (ViroPharma).

  2004cited by this paper
• Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors

  2004cited by this paper
• Correlation between Viral Loads of Cytomegalovirus in Blood and Bronchoalveolar Lavage Specimens from Lung Transplant Recipients Determined by Histology and Immunohistochemistry

  2004cited by this paper
• Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation.

  2004cited by this paper
• Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.

  2004cited by this paper
• Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

  2004cited by this paper
• Validation of Clinical Application of Cytomegalovirus Plasma DNA Load Measurement and Definition of Treatment Criteria by Analysis of Correlation to Antigen Detection

  2004cited by this paper
• Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience.

  2004cited by this paper
• Comparison of LightCycler-Based PCR, COBAS Amplicor CMV Monitor, and pp65 Antigenemia Assays for Quantitative Measurement of Cytomegalovirus Viral Load in Peripheral Blood Specimens from Patients after Solid Organ Transplantation

  2003cited by this paper
• Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation

  2003cited by this paper
• Monitoring of human cytomegalovirus infections in heart transplant recipients by pp65 antigenemia

  2003cited by this paper
• Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis.

  2003cited by this paper
• Combination Prophylaxis with Ganciclovir and Cytomegalovirus (CMV) Immune Globulin After Lung Transplantation: Effective CMV Prevention Following Daclizumab Induction

  2003cited by this paper
• Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients

  2003cited by this paper
• Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality

  2003cited by this paper
• Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study.

  2003cited by this paper
• Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.

  2003cited by this paper
• Cytomegalovirus Disease in High‐Risk Transplant Recipients Despite Ganciclovir or Valganciclovir Prophylaxis

  2003cited by this paper
• Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts.

  2002cited by this paper
• Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.

  2002cited by this paper
• Definitions of cytomegalovirus infection and disease in transplant recipients.

  2002cited by this paper
• Infections in Renal Transplant Recipients Receiving Mycophenolate Versus Azathioprine-Based Immunosuppression

  2002cited by this paper
• A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

  2002cited by this paper
• Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS.

  2002cited by this paper
• Cytomegalovirus matching does not predict symptomatic disease in intestinal transplantation.

  2002cited by this paper
• Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients.

  2002cited by this paper
• Role of the Laboratory in Diagnosis and Management of Cytomegalovirus Infection in Hematopoietic Stem Cell and Solid-Organ Transplant Recipients

  2002cited by this paper
• Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors.

  2002cited by this paper
• Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients.

  2001cited by this paper
• IMPACT OF CYTOMEGALOVIRUS HYPERIMMUNE GLOBULIN ON OUTCOME AFTER CARDIOTHORACIC TRANSPLANTATION: A Comparative Study of Combined Prophylaxis with CMV Hyperimmune Globulin Plus Ganciclovir Versus Ganciclovir Alone

  2001cited by this paper
• Prevention of cytomegalovirus disease in recipients of solid-organ transplants.

  2001cited by this paper
• Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

  2001cited by this paper
• Guide to development of practice guidelines.

  2001cited by this paper
• Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients.

  2001cited by this paper
• Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation

  2001cited by this paper
• RISK FACTORS AND IMPACT OF CYTOMEGALOVIRUS DISEASE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION

  2001cited by this paper
• Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.

  2001cited by this paper
• Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.

  2001cited by this paper
• Management of cytomegalovirus infection and disease after solid-organ transplantation.

  2001cited by this paper
• Posttransplant lymphoproliferative disorders in small bowel allograft recipients.

  2000cited by this paper
• Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients.

  2000cited by this paper
• Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation.

  2000cited by this paper
• CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1: A Randomized, Controlled Trial

  2000cited by this paper
• High‐dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients

  1999cited by this paper
• The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.

  1999cited by this paper
• Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

  1999cited by this paper
• Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation.

  1998cited by this paper
• A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

  1998cited by this paper
• Preemptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients.

  1998cited by this paper
• Infection in organ-transplant recipients.

  1998cited by this paper
• High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes.

  1997cited by this paper
• In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir).

  1997cited by this paper
• Design, synthesis, and antiviral evaluation of 2-chloro-5,6-dihalo-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections.

  1997cited by this paper
• Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase

  1997cited by this paper
• Intravenous Cidofovir for Peripheral Cytomegalovirus Retinitis in Patients with AIDS

  1997cited by this paper
• Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

  1997cited by this paper
• Infectious disease complications of simultaneous pancreas kidney transplantation.

  1997cited by this paper
• Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.

  1997cited by this paper
• Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.

  1996cited by this paper
• Susceptibility of human cytomegalovirus to two-drug combinations in vitro.

  1996cited by this paper
• Epstein Barr virus associated posttransplant lymphoproliferative disease after intestinal transplantation.

  1996cited by this paper
• Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients.

  1996cited by this paper
• Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group.

  1996cited by this paper
• Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.

  1995cited by this paper
• Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.

  1995cited by this paper
• Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients.

  1995cited by this paper
• A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation.

  1995cited by this paper
• Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3

  1995cited by this paper
• Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients

  1995cited by this paper
• Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome.

  1995cited by this paper
• Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients.

  1995cited by this paper
• Cytomegalovirus reactivation and tumour necrosis factor.

  1994cited by this paper
• Ganciclovir for prophylaxis of CMV disease after pancreas/kidney transplantation.

  1994cited by this paper
• Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group.

  1994cited by this paper
• Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand?

  1994cited by this paper
• CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS THE ROLE OF TUMOR NECROSIS FACTOR

  1994cited by this paper
• Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation

  1993cited by this paper
• Prophylaxis and management of cytomegalovirus pneumonitis after lung transplantation: a review of experience in one center.

  1993cited by this paper
• Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens.

  1993cited by this paper
• A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.

  1992cited by this paper
• Single lung transplantation. Factors in postoperative cytomegalovirus infection.

  1991cited by this paper
• Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.

  1991cited by this paper
• Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro

  1990cited by this paper
• Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment.

  1990cited by this paper
• Cytomegalovirus infections in heart and heart-lung transplant recipients.

  1989cited by this paper
• CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study.

  1989cited by this paper
• Risk factors for cytomegalovirus infection after human marrow transplantation.

  1986cited by this paper
• Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients.

  1982cited by this paper

• Enfermedades Infecciosas y Microbiología Clínica

  2022cites this paper
• Assessment of Quantiferon®-CMV and Immuknow® Assays in CMV-seropositive Lung Transplant Recipients to Stratify Risk of CMV Infection.

  2021cites this paper
• Study of cytomegalovirus resistance in allogeneic hematopoietic cell transplant recipients.

  2019cites this paper
• Cytomegalovirus associated with gastric ulcer: case report and literature review.

  2019cites this paper
• UPDATE IN INTENSIVE CARE MEDICINE: CRITICAL PATIENT WITH SERIOUS INFECTION Role of viral infections in immunosuppressed patients

  2017cites this paper
• Herpesviruses excretion in saliva of pediatric transplant recipients

  2017cites this paper
• Impact of Cytomegalovirus Infection on Severe Hepatitis C Recurrence in Patients Undergoing Liver Transplantation

  2016cites this paper
• Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.

  2016cites this paper
• Humanized Monoclonal Antibody Alemtuzumab Treatment in Transplant.

  2016cites this paper
• Étude des mécanismes moléculaires de résistance du cytomégalovirus humain aux antiviraux et évaluation de nouvelles combinaisons thérapeutiques in vitro

  2015cites this paper
• Seroprevalence of Epstein–Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease

  2015cites this paper
• Impact of Donor Cytomegalovirus Serology and duration of Prophylaxis on Follow-Up Strategy in Lung Transplant Recipients

  2015cites this paper
• Infección por citomegalovirus humano

  2014cites this paper
• Prevention strategies for cytomegalovirus disease and long‐term outcomes in the high‐risk transplant patient (D+/R−): experience from the RESITRA‐REIPI cohort

  2014cites this paper
• Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.

  2014cites this paper
• Enfermedades Infecciosas y Microbiología Clínica

  2012influential citation
• Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.

  2012cites this paper
• [Cytomegalovirus infection in renal transplantation: from learned lessons to future challenges].

  2011cites this paper
• [Key definitions and concepts in cytomegalovirus: infection versus disease. Replication, viral load, universal prophylaxis. Preemptive therapy].

  2011cites this paper
• [Treatment of cytomegalovirus disease].

  2011cites this paper
• GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.

  2011cites this paper
• Impact of Hepatitis C Virus Infection on the Risk of Infectious Complications After Kidney Transplantation: Data From the RESITRA/REIPI Cohort

  2011cites this paper
• Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study

  2011cites this paper
• [Lights and shadows of cytomegalovirus infection in solid organ transplantation].

  2011cites this paper
• Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients

  2011cites this paper
• Papel de las infecciones víricas en pacientes inmunodeprimidos

  2011cites this paper
• [Characteristics of antiviral drugs, excluding antiretroviral agents: update 2009].

  2010cites this paper
• Clinical utility of real-time polymerase chain reaction to quantify cytomegalovirus replication in allogeneic stem cell transplant recipients with different prevention strategies.

  2010cites this paper
• Systematic screening and treatment of asymptomatic bacteriuria in renal transplant recipients.

  2010cites this paper
• [Infectious complications in 159 consecutive kidney transplant recipients].

  2009cites this paper
• Incidence and predictive factors for cytomegalovirus infection in renal transplant recipients.

  2009cites this paper
• Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas–kidney transplant recipients

  2009cites this paper
• Prospective study of infectious complications in a cohort of pediatric renal transplant recipients

  2009cites this paper
• Prophylactic therapy with valganciclovir in high-risk (cytomegalovirus D+/R-) kidney transplant recipients: a single-center experience.

  2009cites this paper
• [Descriptive study of infectious complications in 109 consecutive liver transplant recipients].

  2009cites this paper
• Preemptive therapy for cytomegalovirus disease in allogeneic stem cell transplant recipients.

  2008cites this paper
• Indirect effects of cytomegalovirus infection in solid organ transplant recipients.

  2008cites this paper
• Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.

  2008cites this paper
• [Cytomegalovirus infection in kidney transplant patients: what is the best way to prevent it?].

  2008cites this paper
• Viral monitoring and successful treatment of a ganciclovir‐resistant cytomegalovirus infection in a heart transplant recipient

  2008cites this paper
• [A 21-year old male, with a liver transplantation, with short-duration fever, mediastinic lymph nodes and pulmonary infiltrates].

  2008cites this paper
• Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation.

  2008cites this paper
• [The microbiology laboratory: a key participant in transplantation].

  2007cites this paper
• Infecciones transmitidas por el donante

  2007cites this paper
• [Infections in recipients of a kidney-pancreas transplant].

  2007cites this paper
• Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.

  2007cites this paper
• Efectos de la infección viral en el paciente trasplantado

  2007cites this paper
• Infección en el trasplante de pulmón

  2007cites this paper
• [Comparison of two DNA extraction methods for the CMV quantification in blood].

  2006cites this paper
• [Hepatitis due to herpes group viruses].

  2006cites this paper